|
Malignant neoplasm of breast
|
0.350 |
Biomarker
|
disease |
BEFREE |
The efficacy of targeting strategy with FA moieties was demonstrated using the augmented cellular uptake of the FA-conjugated system on overexpressed folate receptor alpha (FRα) cells (MDA-MB-468 breast cancer cell line).
|
31349522 |
2019 |
|
Malignant neoplasm of breast
|
0.350 |
Biomarker
|
disease |
BEFREE |
Our previous identification of degenerate HLA-class II epitopes from human FR led to the development of a broad coverage epitope pool potentially useful in augmenting antigen-specific immune responses in most patients.<b>Patients and Methods:</b> We conducted a phase I clinical trial testing safety and immunogenicity of this vaccine, enrolling patients with ovarian cancer or breast cancer who completed conventional treatment and who showed no evidence of disease.
|
29545464 |
2018 |
|
Malignant neoplasm of breast
|
0.350 |
Biomarker
|
disease |
BEFREE |
Folate receptor alpha (FOLR1) has been identified as a potential prognostic and therapeutic target in breast cancer.
|
28410844 |
2017 |
|
Malignant neoplasm of breast
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
FR-β expression was seen in 21% of ovarian cancer samples, 9% of breast cancer samples, and 55% of colorectal cancer samples.Expression was weak or moderate.
|
26248049 |
2015 |
|
Malignant neoplasm of breast
|
0.350 |
GeneticVariation
|
disease |
BEFREE |
Our findings indicate that Ser1841Asn BRCA1 mutation is able to activate specific protein pathways that are not triggered by other single aminoacid changes and pinpoint to the role TD52 and FOL1 as potential markers in breast cancer patients carrying this particular BRCA1 gene alteration.
|
17005433 |
2007 |
|
Malignant neoplasm of breast
|
0.350 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Neural Tube Defects
|
0.340 |
AlteredExpression
|
group |
BEFREE |
In NTDs, there was an adaptive up-regulation of folate transporters mainly reduced folate carrier (p < 0.001) and folate receptor alpha (p < 0.001).
|
30941645 |
2019 |
|
Neural Tube Defects
|
0.340 |
GeneticVariation
|
group |
BEFREE |
SNP rs651646 (A-->T), located upstream of exon 2 within an intronic region, is polymorphic and is thus a marker for an FRbeta NTD association study.
|
12809644 |
2003 |
|
Neural Tube Defects
|
0.340 |
Biomarker
|
group |
CTD_human |
Arsenic-induced congenital malformations in genetically susceptible folate binding protein-2 knockout mice.
|
11749123 |
2001 |
|
Neural Tube Defects
|
0.340 |
Biomarker
|
group |
BEFREE |
Using a Midwestern NTD population consisting of probands, parents, and siblings from Iowa, Minnesota, and Nebraska, we analyzed a range of candidate genes, including 5,10-methylenetetrahydrofolate reductase (MTHFR), folate receptors-alpha (FOLR1; hereafter abbreviated "FR-alpha") and -beta (FOLR2; hereafter, "FR-beta"), methionine synthase (hereinafter, "MS"), T, the human homolog of the murine Brachyury gene, and the paired-box homeotic gene 3 (PAX3), for association with NTDs.
|
10332959 |
1999 |
|
Neural Tube Defects
|
0.340 |
GeneticVariation
|
group |
BEFREE |
It is unlikely that the beneficial effects of maternal folate supplementation in preventing NTDs acts through a mechanism involving pharmacological correction of a variant form of folate receptor alpha.
|
9545095 |
1998 |
|
Non-alcoholic Fatty Liver Disease
|
0.310 |
Biomarker
|
disease |
CTD_human |
Folate receptor-beta expression as a diagnostic target in human & rodent nonalcoholic steatohepatitis.
|
30794826 |
2019 |
|
Non-alcoholic Fatty Liver Disease
|
0.310 |
AlteredExpression
|
disease |
BEFREE |
Additionally, FR-β expression across the stages of human NAFLD from normal to NASH was assessed.
|
30794826 |
2019 |
|
Nonalcoholic Steatohepatitis
|
0.310 |
AlteredExpression
|
disease |
BEFREE |
Folate receptor-beta expression as a diagnostic target in human & rodent nonalcoholic steatohepatitis.
|
30794826 |
2019 |
|
Nonalcoholic Steatohepatitis
|
0.310 |
Biomarker
|
disease |
CTD_human |
Folate receptor-beta expression as a diagnostic target in human & rodent nonalcoholic steatohepatitis.
|
30794826 |
2019 |
|
Liver Cirrhosis, Experimental
|
0.300 |
Biomarker
|
disease |
CTD_human |
Systems level analysis and identification of pathways and networks associated with liver fibrosis.
|
25380136 |
2014 |
|
Diastematomyelia
|
0.300 |
Biomarker
|
disease |
CTD_human |
Arsenic-induced congenital malformations in genetically susceptible folate binding protein-2 knockout mice.
|
11749123 |
2001 |
|
Neurenteric Cyst
|
0.300 |
Biomarker
|
disease |
CTD_human |
Arsenic-induced congenital malformations in genetically susceptible folate binding protein-2 knockout mice.
|
11749123 |
2001 |
|
Tethered Cord Syndrome
|
0.300 |
Biomarker
|
disease |
CTD_human |
Arsenic-induced congenital malformations in genetically susceptible folate binding protein-2 knockout mice.
|
11749123 |
2001 |
|
Iniencephaly
|
0.300 |
Biomarker
|
disease |
CTD_human |
Arsenic-induced congenital malformations in genetically susceptible folate binding protein-2 knockout mice.
|
11749123 |
2001 |
|
Craniorachischisis
|
0.300 |
Biomarker
|
disease |
CTD_human |
Arsenic-induced congenital malformations in genetically susceptible folate binding protein-2 knockout mice.
|
11749123 |
2001 |
|
Exencephaly
|
0.300 |
Biomarker
|
disease |
CTD_human |
Arsenic-induced congenital malformations in genetically susceptible folate binding protein-2 knockout mice.
|
11749123 |
2001 |
|
Spinal Cord Myelodysplasia
|
0.300 |
Biomarker
|
disease |
CTD_human |
Arsenic-induced congenital malformations in genetically susceptible folate binding protein-2 knockout mice.
|
11749123 |
2001 |
|
Acrania
|
0.300 |
Biomarker
|
disease |
CTD_human |
Arsenic-induced congenital malformations in genetically susceptible folate binding protein-2 knockout mice.
|
11749123 |
2001 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Therefore, a combination of curcumin and paclitaxel at less concentration may be a targeting strategy for FR-targeted drug delivery providing a better therapeutic intervention of cancer.
|
30668349 |
2019 |